-
公开(公告)号：US20220110950A1
公开(公告)日：2022-04-14
申请号：US17560732
申请日：2021-12-23
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
IPC: A61K31/58 , C07J5/00 , A61K31/573 , C07J15/00 , C07J43/00 , C07J7/00 , A61K9/00 , C07J3/00 , C07J13/00 , C07J1/00 , C07J31/00 , C07J21/00
Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US20200155576A1
公开(公告)日：2020-05-21
申请号：US16428386
申请日：2019-05-31
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US20190211054A9
公开(公告)日：2019-07-11
申请号：US15143312
申请日：2016-04-29
Applicant: SAGE THERAPEUTICS, INC.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
CPC classification number: C07J43/003 , C07J3/00 , C07J7/002 , C07J7/007 , C07J7/0085 , C07J13/007 , C07J21/00 , C07J31/006
Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (1): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.
-
公开(公告)号：US10172871B2
公开(公告)日：2019-01-08
申请号：US15297845
申请日：2016-10-19
Applicant: SAGE THERAPEUTICS, INC.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
IPC: A61K31/58 , A61K31/573 , C07J3/00 , C07J7/00 , C07J15/00 , C07J43/00 , A61K9/00 , C07J5/00 , C07J1/00 , C07J13/00 , C07J21/00 , C07J31/00
Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US20170246191A1
公开(公告)日：2017-08-31
申请号：US15297845
申请日：2016-10-19
Applicant: SAGE THERAPEUTICS, INC.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
IPC: A61K31/58 , A61K31/573
CPC classification number: A61K31/58 , A61K9/0019 , A61K31/573 , C07J1/0059 , C07J1/007 , C07J1/0074 , C07J3/00 , C07J5/0015 , C07J5/0053 , C07J7/00 , C07J7/002 , C07J7/007 , C07J7/0085 , C07J13/007 , C07J15/00 , C07J21/00 , C07J31/006 , C07J43/003
Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
Patent Agency Ranking
公开(公告)号：US20240076310A1
公开(公告)日：2024-03-07
申请号：US18482079
申请日：2023-10-06
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
CPC classification number: C07J43/003 , A61P25/08 , A61P25/14 , A61P25/18 , A61P25/20 , A61P25/24 , C07J7/0085 , C07J31/006
Abstract: Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US11912737B2
公开(公告)日：2024-02-27
申请号：US17067093
申请日：2020-10-09
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
CPC classification number: C07J43/003 , C07J1/007 , C07J1/0059 , C07J1/0074 , C07J7/002 , C07J7/007 , C07J7/0085 , C07J13/007 , C07J21/00 , C07J31/006 , C07J71/001
Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I):
and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.-
公开(公告)号：US11344563B2
公开(公告)日：2022-05-31
申请号：US16507214
申请日：2019-07-10
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
IPC: A61K31/58 , C07J7/00 , C07J3/00 , C07J9/00 , C07J17/00 , C07J33/00 , C07J15/00 , C07J43/00 , A61K31/573 , C07J1/00 , C07J13/00 , C07J21/00 , C07J41/00 , C07J5/00 , C07J31/00
Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, and R4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US20210061849A1
公开(公告)日：2021-03-04
申请号：US17094783
申请日：2020-11-10
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US10822370B2
公开(公告)日：2020-11-03
申请号：US16007556
申请日：2018-06-13
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.028 seconds)
